FALSE0001818093Nasdaq00018180932026-09-032026-09-0300018180932026-08-102026-08-100001818093us-gaap:CommonStockMember2026-09-032026-09-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 3, 2026
SkinHealth Systems Inc.
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | |
| Delaware | | 001-39565 | | 85-1908962 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
3600 E. Burnett Street
Long Beach, CA
(Address of principal executive offices)
(800) 603-4996
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
| Class A Common Stock, par value $0.0001 per share | | SKIN | | The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective September 3, 2026, the Board of Directors of SkinHealth Systems Inc. (the “Company”) promoted its Chief Financial Officer, Michael Monahan, to Chief Financial and Operating Officer (the “Promotion”). In connection with Mr. Monahan’s Promotion, he now oversees all of the Company’s financial operations and the Company’s supply chain, manufacturing, logistics, and customer experience. Effective September 15, 2026, Mr. Monahan's base salary will increase from $515,000 to $555,000 as a result of the Promotion.
Biographical information for Mr. Monahan is contained in the Company’s definitive proxy statement, filed with the U.S. Securities and Exchange Commission on April 24, 2026. There are no arrangements or understandings between Mr. Monahan and any other persons pursuant to which he was appointed to the position of Chief Financial and Operating Officer, there are no family relationships between Mr. Monahan and any of the Company’s directors or other executive officers, and there are no transactions between Mr. Monahan and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| Dated: September 10, 2026 | SkinHealth Systems Inc. |
| | |
| By: | /s/ Michael Monahan |
| Name: | Michael Monahan |
| Title: | Chief Financial and Operating Officer |
